Evidence map›Paper›PMID 30213686›Full record

ArticleCellular signalling2018

Ligand-mediated dephosphorylation signaling for MAP kinase.

Nataliia V Shults, Faisal S Almansour, Vladyslava Rybka, Dante I Suzuki, Yuichiro J Suzuki

Open access · greenAbstract read
In one paragraph

Article in Cellular signalling, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Juglone in Oxidative Stress and Cell Signaling.Antioxidants (Basel, Switzerland) · 2019
    Review
  5. Effects of VEGFR1Journal of cancer research and clinical oncology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Nataliia V ShultsDepartment of Pharmacology and Physiology, Georgetown University Medical Center, Washington, DC 20007, USA.
Faisal S AlmansourDepartment of Pharmacology and Physiology, Georgetown University Medical Center, Washington, DC 20007, USA.
Vladyslava RybkaDepartment of Pharmacology and Physiology, Georgetown University Medical Center, Washington, DC 20007, USA.
Dante I SuzukiDepartment of Pharmacology and Physiology, Georgetown University Medical Center, Washington, DC 20007, USA.
Yuichiro J SuzukiDepartment of Pharmacology and Physiology, Georgetown University Medical Center, Washington, DC 20007, USA. Electronic address: ys82@georgetown.edu.
Georgetown University Medical Center · USGeorgetown University · US

Funding

Mechanism of apoptosis in lung vascular smooth muscleR01HL072844 · NHLBI · TUFTS UNIVERSITY BOSTON · PI SUZUKI, YUICHIRO JUSTIN · 2003 to 2017
$3.3M
NHLBI NIH HHS R01 HL072844
6 · The paper itself

Abstract

Extracellular signal-regulated kinase (ERK), also known as classical mitogen-activated protein kinase, plays critical roles in cell regulation. ERK is activated through phosphorylation by a cascade of protein kinases including MEK. Various ligands activate the MEK/ERK pathway through receptor-dependent cell signaling. In cultured cells, many ligands such as growth factors, hormones, cytokines and vasoactive peptides elicit transient activation of MEK/ERK, often peaking at ~10 min after the cell treatment. Here, we describe a novel biological event, in which ligand-mediated cell signaling results in the dephosphorylation of MEK/ERK. Neuromedin N and neurotensin, peptides derived from the same precursor polypeptide, elicit cell signaling through the neurotensin receptors. In cultured human pulmonary artery smooth muscle cells (PASMCs), but not in human pulmonary artery endothelial cells (PAECs), we found that both neuromedin N and neurotensin promoted the dephosphorylation of ERK and MEK. Human PASMCs were found to express neurotensin receptor (NTR)-1, -2 and -3, while human PAECs only express NTR3. Neuromedin N-mediated dephosphorylation was suppressed by small chemical inhibitors of protein phosphatase 1/2A and peptidyl-prolyl isomerase. Transmission electron microscopy showed the formation of endocytic vesicles in response to neuromedin N treatment, and dephosphorylation did not occur when sorting nexin 9, a critical regulator of the endocytic vesicle formation, was knocked down. We conclude that neuromedin N and neurotensin elicit a unique dephosphorylation signaling in the MEK/ERK pathway that is regulated by endocytosis. Considering the pathophysiological importance of the MEK/ERK pathway, this discovery of the dephosphorylation mechanism should advance the field of cell signaling.

Indexed as

Endothelial CellsHumansIntracellular Signaling Peptides and ProteinsMAP Kinase Signaling SystemMyocytes, Smooth MuscleNeurotensinNuclear ProteinsPeptide FragmentsPeptidylprolyl IsomeraseProtease NexinsPulmonary ArteryReceptors, NeurotensinRNA-Binding ProteinsANP32A protein, humanIntracellular Signaling Peptides and Proteinsneuromedin NNeurotensinneurotensin receptor NTR-3neurotensin type 1 receptorNTSR2 protein, humanNuclear ProteinsPeptide FragmentsPeptidylprolyl IsomeraseProtease NexinsReceptors, NeurotensinRNA-Binding ProteinsDephosphorylationEndocytosisMAP kinaseNeuromedin NNeurotensin

Identifiers

PMID30213686
PMCPMC7745923
OpenAlexW2890894351

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.